About Dianomi Therapeutics
Dianomi Therapeutics is a company based in Madison (United States) founded in 2017.. Dianomi Therapeutics has raised $3 million across 3 funding rounds from investors including HHS and Ligand Pharmaceuticals. Dianomi Therapeutics operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Madison, United States
-
Sectors
HealthcareChemicals & Materials
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$3 M (USD)
in 3 rounds
-
Latest Funding Round
$251.88 K (USD), Grant
Sep 01, 2020
-
Investors
HHS
& 1 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Dianomi Therapeutics
Dianomi Therapeutics has successfully raised a total of $3M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $251.88 thousand completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Grant — $251,880
-
First Round
First Round
(25 Jan 2019)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2020 | Amount | Grant - Dianomi Therapeutics | Valuation |
investors |
|
| Feb, 2019 | Amount | Series A - Dianomi Therapeutics | Valuation | Ligand Pharmaceuticals |
|
| Jan, 2019 | Amount | Debt – Conventional - Dianomi Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Dianomi Therapeutics
Dianomi Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Ligand Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical drugs are manufactured and developed in the United States.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Dianomi Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Dianomi Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Dianomi Therapeutics Comparisons
Competitors of Dianomi Therapeutics
Dianomi Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
Dental implants and regenerative dentistry products are developed.
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Dianomi Therapeutics
Frequently Asked Questions about Dianomi Therapeutics
When was Dianomi Therapeutics founded?
Dianomi Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Where is Dianomi Therapeutics located?
Dianomi Therapeutics is headquartered in Madison, United States. It is registered at Madison, Wisconsin, United States.
Who is the current CEO of Dianomi Therapeutics?
Barry Kurokawa is the current CEO of Dianomi Therapeutics.
Is Dianomi Therapeutics a funded company?
Dianomi Therapeutics is a funded company, having raised a total of $3M across 3 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $185K, raised on Jan 25, 2019.
What does Dianomi Therapeutics do?
Dianomi Therapeutics was founded in 2017 in Madison, United States, focusing on the biotechnology sector. Therapies targeting inflammatory conditions, such as osteoarthritis and pain, are developed using a proprietary Mineral Coated Microparticle (MCM) platform. This technology enables sustained drug release and enhances efficacy and safety by mimicking mineralized tissues like bones and teeth. Applications extend to protein biologics and small molecules across various treatments.
Who are the top competitors of Dianomi Therapeutics?
Dianomi Therapeutics's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
Who are Dianomi Therapeutics's investors?
Dianomi Therapeutics has 2 investors. Key investors include HHS, and Ligand Pharmaceuticals.